Novo Nordisk Sees 5% Rise in Shares Following FDA Clearance for Wegovy in Liver Disease

Novo Nordisk's stock experienced a nearly 5% surge on Monday after the company’s well-known obesity medication, Wegovy, was granted fast-track approval by the U.S. Food and Drug Administration for addressing a major liver condition.

The company announced last Friday that it received the green light for utilizing Wegovy to manage metabolic dysfunction-associated steatohepatitis (MASH) among adults with moderate to severe liver fibrosis. This treatment is to be used alongside a diet with reduced calorie intake and increased exercise.

As of 9:59 a.m. London time, which is 4:45 a.m. Eastern Time, Novo Nordisk shares had climbed by 5.05%.